Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05625529 · ClinicalTrials.gov registry record
ExoLuminate Study for Early Detection of Pancreatic Cancer
A clinical trial of Pancreas Cancer and Pancreatic Neoplasms, sponsored by Biological Dynamics.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT05625529: Recruiting study of Pancreas Cancer and Pancreatic Neoplasms, sponsored by Biological Dynamics.
NCT05625529 is a study of Pancreas Cancer and Pancreatic Neoplasms that is actively recruiting participants, run by Biological Dynamics. The registered enrollment target is 1,000 participants, above the 889-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (12% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05625529, a study of Pancreas Cancer and Pancreatic Neoplasms, is actively recruiting participants, sponsored by Biological Dynamics.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC). Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis. The goal of the study is to compare the performance of ExoVerita™ assay in early detection of PDAC to current standard-of-care methods of surveillance.
Primary Outcome
Specificity
Conditions Studied
Study Locations (1)
California
- Biological Dynamics - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2022-12-19 |
| Est. Completion | 2028-01-01 |
What NCT05625529 shows while recruiting
NCT05625529 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 889-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (12% higher).
The record links to 4 conditions, with Pancreas Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT05625529 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05625529 about?
NCT05625529 is a clinical study titled "ExoLuminate Study for Early Detection of Pancreatic Cancer". ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC). Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, f...
What is the current status of trial NCT05625529?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2022-12-19. Estimated completion is 2028-01-01.
What conditions does trial NCT05625529 study?
This clinical trial studies the following conditions: Pancreas Cancer, Pancreatic Neoplasms, Exosomes, Extracellular Vesicles.
Who is sponsoring clinical trial NCT05625529?
This trial is sponsored by Biological Dynamics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05625529 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05625529's enrollment target sits among peer trials
1,000 8th of 54 higher than 47 of 54 other Pancreas Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreas Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RECRUITING
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
The Cancer of the Pancreas Screening-5 CAPS5)Study
RECRUITING · Phase 3
-
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI